Showing 1 - 10 of 327
Persistent link: https://www.econbiz.de/10012439514
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183
We show how characterizing optimal patent policy for the pharmaceutical industry only requires information about generic producers' responses to changes in the effective duration and scope of new drug patents. To estimate these responses, we use data on Paragraph IV patent challenges, and two...
Persistent link: https://www.econbiz.de/10014097057
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012815309
Persistent link: https://www.econbiz.de/10000941760
Persistent link: https://www.econbiz.de/10001392917
Persistent link: https://www.econbiz.de/10001247925
Persistent link: https://www.econbiz.de/10001581918
I calibrate the switching cost for the Finnish retail deposit market by using the approach developed by Oz Shy (2002). It turns out that switching costs faced by deposit customers of the main Finnish banks manifest large variation and are high, ranging from 200 euros to nearly 1,400 euros. Over...
Persistent link: https://www.econbiz.de/10013286483
Persistent link: https://www.econbiz.de/10009680271